The European Commission has granted marketing authorisation to Aquipta (atogepant) for the prophylactic treatment of migraine in adults with at least four migraine days per month. With this approval, atogepant has become the first oral calcitonin gene-related peptide receptor antagonist in the EU for the preventive treatment of both chronic ...